Detailed financial statements for ClearPoint Neuro, Inc. (CLPT): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure.
Analysis Summary
ClearPoint Neuro, Inc. reported revenue of $37.0M in the most recent fiscal year, growing at a 5-year CAGR of 23.6%.
Trailing-twelve-month margins: gross margin 62.6%, operating margin -73.4%, net margin -81.8%.
At the current price of $13.40, CLPT has negative trailing earnings (P/E not meaningful) and an ROE of -188.09%. Market capitalisation stands at $402M.
Balance sheet quality for CLPT: current ratio of 5.9, net debt of $12.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7M | $7.4M | $7.4M | $11.2M | $12.8M | $16.3M | $20.6M | $24.0M | $31.4M | $37.0M |
| Cost of Revenue | $2.6M | $2.9M | $2.4M | $3.9M | $3.7M | $5.2M | $7.0M | $10.3M | $12.3M | $14.3M |
| Gross Profit | $3.1M | $4.5M | $4.9M | $7.3M | $9.1M | $11.1M | $13.5M | $13.6M | $19.1M | $22.7M |
| Research & Development | $2.6M | $2.8M | $2.3M | $2.8M | $4.7M | $9.3M | $10.9M | $11.7M | $12.4M | $13.9M |
| Selling, General & Admin | $8.0M | $8.0M | $7.9M | $9.1M | $10.7M | $15.2M | $19.0M | $24.4M | $26.5M | $33.0M |
| Operating Expenses | $10.6M | $10.8M | $10.2M | $11.9M | $15.3M | $24.5M | $29.9M | $36.1M | $38.9M | $46.9M |
| Operating Income | -$7.5M | -$6.3M | -$5.2M | -$4.6M | -$6.2M | -$13.4M | -$16.3M | -$22.4M | -$19.7M | -$24.2M |
| EBITDA | -$6.9M | -$6.2M | -$5.1M | -$4.3M | -$4.8M | -$12.7M | -$15.6M | -$20.6M | -$17.0M | -$20.9M |
| Interest Expense | $1.1M | $872926 | $980383 | $955000 | $1.4M | $973000 | $81000 | 0 | 0 | $2.4M |
| Pre-tax Income | -$8.1M | -$7.2M | -$6.2M | -$5.5M | -$6.8M | -$14.4M | -$16.4M | -$22.1M | -$18.9M | -$25.5M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $55000 |
| Net Income | -$8.1M | -$7.2M | -$6.2M | -$5.5M | -$6.8M | -$14.4M | -$16.4M | -$22.1M | -$18.9M | -$25.5M |
| EPS | $-2.93 | $-0.93 | $-0.56 | $-0.49 | $-0.43 | $-0.69 | $-0.68 | $-0.90 | $-0.70 | $-0.90 |
| EPS (Diluted) | $-2.93 | $-0.93 | $-0.56 | $-0.49 | $-0.43 | $-0.69 | $-0.68 | $-0.90 | $-0.70 | $-0.90 |
| Shares Outstanding (Diluted) | $2.8M | $7.7M | $10.9M | $13.2M | $15.8M | $20.7M | $24.2M | $24.6M | $27.0M | $28.3M |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.3M | $9.3M | $3.1M | $5.7M | $20.1M | $54.1M | $27.6M | $23.1M | $20.1M | $45.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | $9.9M | 0 | 0 | 0 |
| Receivables | $865943 | $949415 | $1.2M | $1.1M | $1.9M | $2.3M | $2.7M | $3.9M | $4.7M | $7.3M |
| Inventory | $1.8M | $2.3M | $2.1M | $3.2M | $3.2M | $4.9M | $9.3M | $7.9M | $6.9M | $8.4M |
| Total Current Assets | $6.1M | $12.7M | $6.7M | $10.4M | $25.5M | $61.9M | $51.2M | $36.2M | $33.4M | $63.6M |
| Property, Plant & Equipment | $328249 | $267667 | $377706 | $821000 | $3.1M | $2.8M | $2.7M | $5.0M | $5.1M | $11.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $7.5M |
| Intangible Assets | 0 | 0 | 0 | 0 | $353000 | $265000 | $1.0M | $1.0M | $484000 | $13.9M |
| Total Assets | $7.4M | $13.9M | $7.9M | $11.9M | $29.5M | $65.6M | $55.5M | $42.7M | $39.2M | $97.7M |
| Accounts Payable | $1.5M | $759445 | $500928 | $966000 | $300000 | $427000 | $272000 | $393000 | $1.3M | $1.3M |
| Short-term Debt | 0 | $2.0M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.0M | $4.4M | $2.0M | $3.8M | $3.2M | $4.8M | $6.8M | $7.4M | $10.4M | $10.8M |
| Long-term Debt | $4.5M | $2.9M | $3.5M | $2.1M | $21.3M | $9.8M | $9.9M | $9.9M | 0 | $49.1M |
| Total Liabilities | $8.2M | $8.1M | $6.3M | $7.3M | $27.1M | $16.8M | $18.6M | $21.5M | $13.8M | $69.7M |
| Retained Earnings | -$93.9M | -$101.0M | -$107.2M | -$112.7M | -$119.5M | -$133.9M | -$150.4M | -$172.5M | -$191.4M | -$216.9M |
| Total Equity | -$756069 | $5.8M | $1.5M | $4.6M | $2.4M | $48.8M | $36.9M | $21.2M | $25.4M | $28.0M |
| Total Debt | $4.5M | $4.9M | $3.5M | $2.5M | $24.1M | $12.3M | $12.0M | $13.9M | $3.6M | $58.2M |
| Net Debt | $1.2M | -$4.4M | $379508 | -$3.2M | $4.0M | -$41.8M | -$25.5M | -$9.2M | -$16.5M | $12.3M |
| Working Capital | $3.1M | $8.3M | $4.6M | $6.6M | $22.3M | $57.1M | $44.4M | $28.7M | $23.0M | $52.8M |
Cash Flow (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$8.1M | -$7.2M | -$6.2M | -$5.5M | -$6.8M | -$14.4M | -$16.4M | -$22.1M | -$18.9M | -$25.5M |
| Depreciation & Amortization | $155707 | $116454 | $109439 | $250560 | $553000 | $692000 | $777000 | $1.5M | $1.9M | $982000 |
| Stock-based Compensation | $959585 | $1.2M | $1.2M | $799110 | $1.1M | $2.1M | $4.1M | $6.1M | $6.9M | $8.2M |
| Change in Working Capital | $672221 | -$1.1M | -$383652 | $911319 | -$2.7M | -$1.7M | -$4.3M | -$1.4M | $1.4M | -$9.8M |
| Operating Cash Flow | -$5.8M | -$6.0M | -$4.6M | -$2.8M | -$7.8M | -$12.7M | -$16.2M | -$13.7M | -$8.9M | -$23.9M |
| Capital Expenditure | -$101002 | -$26752 | -$63490 | -$160190 | -$482000 | -$168000 | -$253000 | -$717000 | -$275000 | -$522000 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.1M |
| Stock Repurchased | -$4756 | 0 | 0 | 0 | 0 | 0 | 0 | -$210000 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | -$5.9M | -$6.0M | -$4.7M | -$3.0M | -$8.3M | -$12.9M | -$16.4M | -$14.4M | -$9.2M | -$24.4M |
Growth & Margins (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | +28.4% | -0.4% | +52.5% | +14.4% | +27.0% | +26.1% | +16.6% | +31.0% | +17.8% | |
| Net Income Growth (YoY) | +11.2% | +14.0% | +10.1% | -22.4% | -112.5% | -14.1% | -34.4% | +14.4% | -35.0% | |
| EPS Growth (YoY) | +68.3% | +39.8% | +12.5% | +12.2% | -60.5% | +1.4% | -32.4% | +22.2% | -28.6% | |
| Shares Change (YoY) | +180.9% | +41.2% | +20.4% | +20.5% | +30.8% | +16.6% | +1.8% | +9.8% | +4.8% | |
| FCF Growth (YoY) | -1.7% | +22.0% | +35.9% | -175.4% | -55.2% | -27.6% | +12.1% | +36.1% | -165.0% | |
| Gross Margin | 54.0% | 60.7% | 66.9% | 64.9% | 71.1% | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Operating Margin | -130.3% | -85.9% | -71.4% | -41.0% | -48.5% | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| EBITDA Margin | -119.2% | -83.7% | -69.0% | -38.6% | -37.3% | -78.2% | -75.8% | -86.1% | -54.2% | -56.4% |
| Net Margin | -140.4% | -97.1% | -83.8% | -49.4% | -52.9% | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| FCF Margin | -103.0% | -81.6% | -63.8% | -26.8% | -64.6% | -78.9% | -79.9% | -60.3% | -29.4% | -66.1% |
| Effective Tax Rate | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.2% |
Per-Share Data (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $-2.15 | $-0.78 | $-0.43 | $-0.23 | $-0.52 | $-0.62 | $-0.68 | $-0.59 | $-0.34 | $-0.86 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $2.8M | $7.7M | $10.9M | $13.2M | $15.8M | $20.7M | $24.2M | $24.6M | $27.0M | $28.3M |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Profitability
| Return on Equity | -188.09% |
| Return on Invested Capital | -40.49% |
| Return on Assets | -39.85% |
| Gross Margin | 62.61% |
| Operating Margin | -73.42% |
| Net Margin | -81.76% |
Financial Health
| Debt / Equity | 5.93 |
| Current Ratio | 4.73 |
Key Ratios (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | -1.16 | -2.96 | -2.80 | -9.80 | -36.95 | -16.26 | -12.46 | -7.54 | -21.97 | -15.20 |
| P/B | -12.39 | 3.65 | 11.35 | 13.77 | 105.95 | 4.77 | 5.55 | 7.89 | 16.37 | 13.82 |
| P/S | 1.63 | 2.88 | 2.33 | 5.63 | 19.63 | 14.27 | 9.97 | 6.97 | 13.24 | 10.48 |
| Gross Margin | 54.0% | 60.7% | 66.9% | 64.9% | 71.1% | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Operating Margin | -130.3% | -85.9% | -71.4% | -41.0% | -48.5% | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Net Margin | -140.4% | -97.1% | -83.8% | -49.4% | -52.9% | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
Related companies: AKBA · AVNS · CMPS · CTKB · LAB · OFIX · SIBN
Explore sector: Healthcare · Medical - Devices
More sections of CLPT: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks